Wednesday, March 29, 2023
Evotec announced that it has extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb originally signed in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programmes. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for additional 8 years with the goal to further broaden and deepen the strategic alliance.
Evotec and Bristol Myers Squibb initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. This partnership pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s modality-agnostic precision medicine platforms. The partnership is already successful in generating a pipeline of discovery and pre-clinical-stage programmes.
Together, an exceptional group of multidisciplinary experts are built for large-scale patient-specific biological and analytical systems to identify, validate and develop new targets for the treatment of neurodegenerative diseases.
